Preclinical rodent toxicity studies for long term use of ceftriaxone

Toxicology Reports

Volumn 2, Issue , 2015, Pages 1396-1403

  Ratti, Elena ^a   Berry, James D ^a   Greenblatt, David J ^b   Loci, Lorena ^a,d   Ellrodt, Amy Swartz ^a   Shefner, Jeremy M ^c,e   Cudkowicz, Merit E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d BOSTON COLLEGE   (United States)

^e BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Amyotrophic lateral sclerosis (ALS); Ceftriaxone; Pharmacokinetics; Preclinical study; Rodent; Toxicology

Indexed keywords

CEFTRIAXONE; PLACEBO;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BILE DUCT DILATATION; BLEEDING; BLOOD ANALYSIS; BODY WEIGHT; CECUM DISEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INJECTION SITE SWELLING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MORTALITY; NONHUMAN; ORGAN WEIGHT; RAT; SKIN DISEASE; STOMACH DISEASE; TOXICITY TESTING; URINALYSIS;

EID: 84945262717     PISSN: 22147500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxrep.2015.09.010     Document Type: Article

References (28)

1. B. Braun Medical Inc., C.U., CefTRIaxONE for Injection and Dextrose Injection Package Insert, pp. 2009.
2. Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.G., Bolger A.F., Levison M.E., Ferrieri P., Gerber M.A., Tani L.Y., Gewitz M.H., Tong D.C., Steckelberg J.M., Baltimore R.S., Shulman S.T., Burns J.C., Falace D.A., Newburger J.W., Pallasch T.J., Takahashi M., Taubert K.A. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-434.
3. Beam T.R. Ceftriaxone: a beta- lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy 1985, 5:237-253.
4. Berry J.D., Shefner J.M., Conwit R., Schoenfeld D., Keroack M., Felsenstein D., Krivickas L., David W.S., Vriesendorp F., Pestronk A., Caress J.B., Katz J., Simpson E., Rosenfeld J., Pascuzzi R., Glass J., Rezania K., Rothstein J.D., Greenblatt D.J., Cudkowicz M.E. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013, 8:e61177.
5. Bolton W.K., Benton F.R., Maclay J.G., Sturgill B.C. Spontaneous glomerular sclerosis in aging Sprague-Dawley rats: I. Lesions associated with mesangial IgM deposits. Am. J. Pathol. 1976, 85:277-302.
6. Bor O., Dinleyici E.C., Kebapci M., Aydogdu S.D. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr. Int. 2004, 46:322-324.
7. Chio A., Logroscino G., Traynor B.J., Collins J., Simeone J.C., Goldstein L.A., White L.A. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013, 41:118-130.
8. Chu K., Lee S.T., Sinn D.I., Ko S.Y., Kim E.H., Kim J.M., Kim S.J., Park D.K., Jung K.H., Song E.C., Lee S.K., Kim M., Roh J.K. Pharmacological Induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007, 38:177-182.
9. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products Note for guidance on repeated dose toxicity, pp. 2000.
10. Cudkowicz M.E., Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D., Hayden D., Shui A., Brooks B., Conwit R., Felsenstein D., Greenblatt D.J., Keroack M., Kissel J.T., Miller R., Rosenfeld J., Rothstein J.D., Simpson E., Tolkoff- Rubin N., Zinman L., Shefner J.M. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014, 13:1083-1091.
11. Guarino M.P., Cocca S., Altomare A., Emerenziani S., Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J. Gastroenterol. 2013, 19:5029-5034.
12. Hardiman O., van den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7:639-649.
13. Heemskerk J. Screening existing drugs for neurodegeneration: the National Institute of Neurologic Disorders and Stroke (NINDS) model. Retina 2005, 25:S56-S57.
14. ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Note for Guidance on Toxicokinetics: The Assessment of Systematic Exposure in Toxicity Studies S3A, pp. 1994.
15. Lipski J., Wan C.K., Bai J.Z., Pi R., Li D., Donnelly D. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 2007, 146:617-629.
16. McKee J.S., Gass J.H. Acetaminophen-induced forestomach lesion in normal rats following intravenous exposure. Toxicol. Pathol. 2011, 39:861-866.
17. Melzer N., Meuth S.G., Torres- Salazar D., Bittner S., Zozulya A.L., Weidenfeller C., Kotsiari A., Stangel M., Fahlke C., Wiendl H. A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One 2008, 3:e3149.
18. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
19. Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, 3:CD001447.
20. Nizzardo M., Nardini M., Ronchi D., Salani S., Donadoni C., Fortunato F., Colciago G., Falcone M., Simone C., Riboldi G., Govoni A., Bresolin N., Comi G.P., Corti S. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp. Neurol. 2011, 229:214-225.
21. Rivera M., Garcia- Herrera A.L., Burguera V., Sosa-Barrios H., Palomares J.R., Quereda C. Ceftriaxone-associated gallbladder pseudolithiasis in a PD patient. Perit. Dial. Int. 2011, 31:97-99.
22. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta- lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
23. Thone-Reineke C., Neumann C., Namsolleck P., Schmerbach K., Krikov M., Schefe J.H., Lucht K., Hortnagl H., Godes M., Muller S., Rumschussel K., Funke-Kaiser H., Villringer A., Steckelings U.M., Unger T. The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J. Hypertens. 2008, 26:2426-2435.
24. Turner M.R., Parton M.J., Shaw C.E., Leigh P.N., Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J. Neurol. Neurosurg. Psychiatry 2003, 74:995-997.
25. van Ogtrop M.L., Guiot H.F., Mattie H., van Furth R. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. Antimicrob. Agents Chemother. 1991, 35:976-982.
26. Vincent A.M., Backus C., Taubman A.A., Feldman E.L. Identification of candidate drugs for the treatment of ALS. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2005, 6:29-36.
27. Xia Y., Lambert K.J., Schteingart C.D., Gu J.J., Hofmann A.F. Concentrative biliary secretion of ceftriaxone: inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 1990, 99:454-465.
28. Zhao Y., Cudkowicz M.E., Shefner J.M., Krivickas L., David W.S., Vriesendorp F., Pestronk A., Caress J.B., Katz J., Simpson E., Rosenfeld J., Pascuzzi R., Glass J., Rezania K., Harmatz J.S., Schoenfeld D., Greenblatt D.J. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J. Clin. Pharmacol. 2014, 54:1180-1187.